Should I buy or sell Kymera Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KYMR shares. View KYMR analyst ratings or view top-rated stocks .

What is Kymera Therapeutics' stock price target for 2024?

12 analysts have issued 12-month price targets for Kymera Therapeutics' stock. Their KYMR share price targets range from $24.00 to $56.00. On average, they expect the company's stock price to reach $39.89 in the next twelve months. This suggests a possible upside of 13.6% from the stock's current price. View analysts price targets for KYMR or view top-rated stocks among Wall Street analysts .

How have KYMR shares performed in 2024?

Kymera Therapeutics' stock was trading at $25.46 at the beginning of 2024. Since then, KYMR stock has increased by 37.9% and is now trading at $35.12. View the best growth stocks for 2024 here .

Are investors shorting Kymera Therapeutics?

Kymera Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 9,060,000 shares, an increase of 8.8% from the March 15th total of 8,330,000 shares. Based on an average trading volume of 752,000 shares, the short-interest ratio is currently 12.0 days. View Kymera Therapeutics' Short Interest .

When is Kymera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our KYMR earnings forecast .

How were Kymera Therapeutics' earnings last quarter?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) announced its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.19. The company earned $47.90 million during the quarter, compared to analysts' expectations of $41.94 million. Kymera Therapeutics had a negative trailing twelve-month return on equity of 34.83% and a negative net margin of 187.00%. The business's revenue for the quarter was up 197.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.60) earnings per share.

What ETFs hold Kymera Therapeutics' stock?

ETFs with the largest weight of Kymera Therapeutics (NASDAQ:KYMR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Simplify Propel Opportunities ETF (SURI) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of Kymera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI) , Gores Holdings V (GRSVU) , FS Development (FSDC) , Freeline Therapeutics (FRLN) , Duck Creek Technologies (DCT) , CureVac (CVAC) , Checkmate Pharmaceuticals (CMPI) , Burlington Stores (BURL) , BigCommerce (BIGC) and KE (BEKE) .

When did Kymera Therapeutics IPO?

Kymera Therapeutics (KYMR) raised $126 million in an IPO on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

Who are Kymera Therapeutics' major shareholders?

Kymera Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (0.08%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Bruce Booth , Bruce N Jacobs, Bruce N Jacobs , Bvf Partners L P/Il, Ellen Chiniara, Jared Gollob , Jeffrey W Albers, Nello Mainolfi , Richard Chesworth and Venture Fund X LP Atlas. View institutional ownership trends .

How do I buy shares of Kymera Therapeutics?

Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KYMR

Kymera Therapeutics (KYMR) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free KYMR Stock Alerts

$35.12

+1.36 (+4.03%)

(As of 04/18/2024 ET)

Compare

Today's Range: $33.67
▼
$35.57
50-Day Range: $33.76
▼
$43.57
52-Week Range: $9.60
▼
$45.31

Volume: 619,727 shs
Average Volume: 470,062 shs
Market Capitalization: $2.15 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $39.89

Get Kymera Therapeutics alerts:

Kymera Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 13.6% Upside
$39.89 Price Target
Short Interest: Bearish
14.83% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.82
Based on 4 Articles This Week
Insider Trading: Selling Shares
$19.92 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.13) to ($3.42) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.82 out of 5 stars

Medical Sector

827th out of 918 stocks

Biological Products, Except Diagnostic Industry

144th out of 155 stocks

3.3

Analyst's Opinion

Consensus Rating
Kymera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Kymera Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
14.83% of the outstanding shares of Kymera Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Kymera Therapeutics has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.
Change versus previous month
Short interest in Kymera Therapeutics has recently increased by 8.76%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Kymera Therapeutics does not currently pay a dividend.
Dividend Growth
Kymera Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KYMR.

2.7

News and Social Media Coverage

News Sentiment
Kymera Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Kymera Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for KYMR on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kymera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,924,711.00 in company stock.
Percentage Held by Insiders
16.67% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Kymera Therapeutics are expected to decrease in the coming year, from ($3.13) to ($3.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kymera Therapeutics is -13.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kymera Therapeutics is -13.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kymera Therapeutics has a P/B Ratio of 4.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Kymera Therapeutics Stock (NASDAQ:KYMR)

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

KYMR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KYMR Stock News Headlines

April 16, 2024 | americanbankingnews.com

Short Interest in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Increases By 8.8%

April 12, 2024 | americanbankingnews.com

Q1 2024 EPS Estimates for Kymera Therapeutics, Inc. Lifted by Analyst (NASDAQ:KYMR)

April 19, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

April 8, 2024 | finanznachrichten.de

Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

April 8, 2024 | globenewswire.com

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

March 28, 2024 | investing.com

Kymera Therapeutics Inc (KYMR)

March 20, 2024 | finance.yahoo.com

KYMR May 2024 30.000 call

March 19, 2024 | finance.yahoo.com

KYMR Aug 2024 20.000 put

April 19, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

March 18, 2024 | bizjournals.com

Biotech upgrades to new Watertown digs with triple the space

March 8, 2024 | globenewswire.com

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

March 5, 2024 | finance.yahoo.com

Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR)

March 3, 2024 | finance.yahoo.com

Analysts' Revenue Estimates For Kymera Therapeutics, Inc. (NASDAQ:KYMR) Are Surging Higher

February 28, 2024 | globenewswire.com

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

February 27, 2024 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

February 27, 2024 | markets.businessinsider.com

Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know

February 26, 2024 | markets.businessinsider.com

Maintaining Hold on Kymera Therapeutics Amidst Promising Pipeline and Industry Challenges

February 24, 2024 | finance.yahoo.com

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Trimming Their Forecasts

February 24, 2024 | benzinga.com

Kymera Therapeutics Stock (NASDAQ:KYMR) Dividends: History, Yield and Dates

February 23, 2024 | markets.businessinsider.com

Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views

February 23, 2024 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)

February 23, 2024 | finance.yahoo.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript

February 23, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Morphic Holding (MORF)

February 23, 2024 | finance.yahoo.com

Q4 2023 Kymera Therapeutics Inc Earnings Call

February 22, 2024 | finanznachrichten.de

Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

February 22, 2024 | finance.yahoo.com

Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results

February 22, 2024 | globenewswire.com

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

See More Headlines

Receive KYMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:KYMR
CUSIP: N/A
CIK: 1815442
Web: www.kymeratx.com
Phone: 857-285-5300
Fax: N/A
Employees: 187
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $39.89
High Stock Price Target: $56.00
Low Stock Price Target: $24.00
Potential Upside/Downside: +13.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-146,960,000.00
Net Margins: -187.00%
Pretax Margin: -186.99%
Return on Equity: -34.83%
Return on Assets: -25.30%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.73
Quick Ratio: 4.73

Sales & Book Value

Annual Sales: $78.59 million
Price / Sales: 27.31
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.12 per share
Price / Book: 4.93

Miscellaneous

Outstanding Shares: 61,110,000
Free Float: 50,925,000
Market Cap: $2.15 billion
Optionable: Optionable
Beta: 2.27

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Bruce L. Booth DPHIL (Age 50)
Ph.D., Co-Founder & Chairman
Comp: $79.19k
Dr. Nello Mainolfi M.D. (Age 46)
Ph.D., Co-Founder, President, CEO & Director
Comp: $975.2k
Mr. Bruce N. Jacobs CFA
Chief Financial Officer
Dr. Jared A. Gollob M.D. (Age 59)
Chief Medical Officer
Comp: $637.81k
Dr. Jeremy G. Chadwick Ph.D. (Age 61)
Chief Operating Officer
Ms. Ellen V. Chiniara Esq. (Age 65)
J.D., Chief Legal Officer & Corporate Secretary
Ms. Karen Weisbach
Head of People & Culture
Dr. Juliet Williams B.A Ph.D.
Head of Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KYMR Stock Analysis - Frequently Asked Questions

Should I buy or sell Kymera Therapeutics stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KYMR shares.
View KYMR analyst ratings or view top-rated stocks.
What is Kymera Therapeutics' stock price target for 2024?: 12 analysts have issued 12-month price targets for Kymera Therapeutics' stock. Their KYMR share price targets range from $24.00 to $56.00. On average, they expect the company's stock price to reach $39.89 in the next twelve months. This suggests a possible upside of 13.6% from the stock's current price.
View analysts price targets for KYMR or view top-rated stocks among Wall Street analysts.
How have KYMR shares performed in 2024?: Kymera Therapeutics' stock was trading at $25.46 at the beginning of 2024. Since then, KYMR stock has increased by 37.9% and is now trading at $35.12.
View the best growth stocks for 2024 here.
Are investors shorting Kymera Therapeutics?: Kymera Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 9,060,000 shares, an increase of 8.8% from the March 15th total of 8,330,000 shares. Based on an average trading volume of 752,000 shares, the short-interest ratio is currently 12.0 days.
View Kymera Therapeutics' Short Interest.
When is Kymera Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our KYMR earnings forecast.
How were Kymera Therapeutics' earnings last quarter?: Kymera Therapeutics, Inc. (NASDAQ:KYMR) announced its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.19. The company earned $47.90 million during the quarter, compared to analysts' expectations of $41.94 million. Kymera Therapeutics had a negative trailing twelve-month return on equity of 34.83% and a negative net margin of 187.00%. The business's revenue for the quarter was up 197.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.60) earnings per share.

What ETFs hold Kymera Therapeutics' stock?: ETFs with the largest weight of Kymera Therapeutics (NASDAQ:KYMR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Clinical Trials ETF (BBC).
What other stocks do shareholders of Kymera Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE).
When did Kymera Therapeutics IPO?: Kymera Therapeutics (KYMR) raised $126 million in an IPO on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO.
Who are Kymera Therapeutics' major shareholders?: Kymera Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (0.08%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Bruce Booth, Bruce N Jacobs, Bruce N Jacobs, Bvf Partners L P/Il, Ellen Chiniara, Jared Gollob, Jeffrey W Albers, Nello Mainolfi, Richard Chesworth and Venture Fund X LP Atlas.
View institutional ownership trends.
How do I buy shares of Kymera Therapeutics?: Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KYMR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kymera Therapeutics (KYMR) Stock Price, News & Analysis

Kymera Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Kymera Therapeutics Stock (NASDAQ:KYMR)

KYMR Stock Price History

KYMR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KYMR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™